Onco Wiki / Maladie

Carcinome oesophagien (squame + adeno)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-ESOPHAGEAL
TypeMaladie
Alias
CSC oesophagienne + adénocarcinomeCancer de l'oesophageCarcinome de l'oesophageКарцинома стравоходу (плоскоклітинна + аденокарцинома)
Étatreviewed 2026-04-26 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8070/3
icd_o_3_topography["C15"]
icd_10C15
who_classificationWHO Digestive System Tumours 5th ed: Esophageal squamous cell carcinoma + esophageal adenocarcinoma

Capacités

Notes

Scaffolded for Phase GI-1: 1 RF (high-grade dysphagia / aspiration — most common acute presentation), 1 indication (CROSS-style scaffold noting RT not modellable), 1 algorithm. Full histology-stratified algorithm (squamous: definitive CRT for unresectable, CROSS for resectable; adeno: FLOT preferred for resectable, CROSS alternative) + adjuvant nivolumab post-CROSS without pCR + metastatic biomarker- stratified ICI/chemo combos await ratification + clinical authoring. Histology branching is critical — squamous and adeno have largely parallel but partially divergent paradigms. Per-prompt allowance: one disease YAML covers both, with histology field on Indication applicability.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Procédures

Questionnaires

Signal d’alerte

Sources